Terrano, Christine Grace .
HRN: 22-96-20 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2023
CO-AMOXICLAV 625MG (TAB)
06/02/2023
06/09/2023
PO
625mg
BID
S/P NSVD With 2nd Degree Laceration And Repair
Waiting Final Action
Indication: Prophylaxis Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes